Rheumatology Flashcards
Symptoms suggestive of rheumatic disease
joint pain
fever
fatigue
rash
Arthralgia WITHOUT physical findings of arthritis suggests
infection malignancy orthopedic conditions benign syndromes pain syndromes like fibromyalgia
Kawasaki Disease (Mucocutaneous Lymph Node Syndrome)
FEVER for at least 5 days + 4 of the ff
CRASH
Conjunctivitis - bilateral, bulbar injection (-) exudate
Rash
Adenopathy - solitary, cervical adenopathy > 1.5 cm
Strawberry tongue and other oropharyngeal changes
Hand changes - brawny edema, induration, peeling around the nail beds
Common in ACUTE phase especially in younger then 1 y/o patients
PERINEAL DESQUAMATION
Begins 1-3 weeks AFTER the onset of illness
PERIUNGUAL DESQUAMATION
Develop in the 2nd-3rd week of illness in untreated cases
Coronary Artery Aneurysms
Clinical phases of Kawasaki Disease
Acute Febrile
Subacute
Convalescent
Lasts 1-2- weeks; fever and other acute signs of illness
Acute Febrile Phase
Begins when fever and other signs have abated
Highest risk of sudden death in those who developed aneurysms
Lasts until 4 weeks
Subacute Phase
Begins when all clinical signs have disappeared and continues until ESR and CRP return to normal
Convalescent Phase
Any infant or child with 5 or more days of fever with 2-3 of the principal clinical features but have compatible laboratory findings
May have manifestations such as – renal failure, unilateral facial nerve palsy, pulmonary infiltrates
Atypical Kawasaki Disease
Considered in all children with unexpected fever for 5 or more days with 3 or less of the clinical criteria
More common in young infants
Incomplete Kawasaki Disease
This should be performed at diagnosis of Kawasaki and repeated after 2-3 weeks of illness
If both are normal – repeat study after 6-8 weeks
2D-Echo
Treatment of Kawasaki Disease
Acute Stage
IVIg 2 g/kg over 10-12 hrs
Aspirin 80-100
Treatment of Kawasaki Disease
Convalescent Stage
Aspirin 3-5 mg/kg OD daily until 6-8 weeks
Long term therapy for patients w/ Coronary Abnormalities
Aspirin 3-5 mg
Clopidogrel 1 mg/kg/day
Warfarin or LMWH
Persistent of recrudescent fever 36 hr after completion of the initial IVIG infusion
INCREASED RISK FOR CAA
IVIG Resistant KD
give another dose of IVIG at 2 g/kg
methylprednisolone - if poor response pa din
Serious, rare condition in children in which the body’s own immune system overreacts to a stimulus
Results in inflammation of multiple organ systems → leads to impaired organ function and organ failure
Diagnosed in <21 years of age in mostly Europe and the USA
Unknown cause
Mounting evidence that is linked to COVID-19
Multisystem Inflammatory Syndrome in Children (MIS-C)
HEART - commonly affected
MIS-C
Patient is 21 years of age or younger and has had a fever of 38°C for at least 24 hours
blood work shows indications of inflammation
requires treatment at a hospital (often in the intensive care unit)
due to severe illness that includes dysfunction of two or more organs, particularly the heart, blood vessels, GI organs, lungs, kidneys, skin, eyes, or nervous system
The MC of pediatric inflammatory myopathies
Systemic vasculopathy with characteristic cutaneous findings and focal areas of myositis – progressive proximal muscle weakness
JUVENILE DERMATOMYOSITIS
Gottron papules
Heliotrope eyelids/Heliotrope rash
Shawl sign
Clinical manifestations of Juvenile Dermatomyositis
Neck flexor or abdominal muscle weakness
Unable to sit up or head lag during infancy, and Gower sign (use of hands on thighs to stand from a sitting position)
Derangement of upper airway function
Dysphagia - severe prognostic sign
Constipation, abdominal pain, or diarrhea
Dilated cardiomyopathy
Diagnostic Criteria for Juvenile Dermatomyositis
Classic rash (Heliotrope rash of the eyelids, Gottron papules)
PLUS 3 of the ff
weakness (symmetric, proximal)
muscle enzyme elevation equal or >1 (CK, aspartate aminotransferase, LDH, aldolase)
electromyographic changes (myopathy, denervation)
muscle biopsy (necrosis, inflammation)
Diagnosis and Lab Findings in Juvenile Dermatomyositis
PE - nailfold of capillaries show periungual avascularity with capillary dropout and vessel dilatation with terminal bush formation
ALANINE AMINOTRANSFERASE
Antibodies to Pm/Scl
MRI
Confirms diagnosis of Juvenile Dermatomyositis if the clinical and lab manifestations are inconclusive
Muscle Biopsy
Treatment for Juvenile Dermatomyositis
Corticosteroids
Methotrexate
Folic acid
IVIG
7 y/o
rash - raised, pinkish to erythematous purpuric lesions – buttocks to the lower extremities
R knee pain
HENOCH SCHONLEIN PURPURA
IgA mediated vasculitis of small vessels (dermal capillaries and postcapillary venules)
3-10 y/o
linked with NEPHRITIS: HLA B34 and HLA DRB1*01
PALPABLE PURPURA IN THE DEPENDENT PARTS
Treatment of HSP
symptomatic
self limiting
STEROIDS - severe abdominal pain and joint pain
SERIAL URINALYSIS for 6 mos after diagnosis
Skin biopsy result of HSP
leukocytoclastic angiitis
Renal biopsy result of HSP
IgA mesangial deposition
Systemic JIA
fever
rash
joint pain
swelling
Arthritis in equal or > 1 joints with or preceded by fever for at least 2 weeks in duration documented to be daily for at least 3 days and accompanied by 1 or more of the ff
- Evanescent erythematous rash
- Generalized lymph node enlargement
- Hepatomegaly or splenomegaly or both
- Serositis
Oligoarthritis JIA
Arthritis affecting 1-4 joints during the 1st 6 mos
Pharmacologic Treatment of Juvenile Idiopathic Arthritis
NSAIDS
Naproxen
Ibuprofen
Meloxicam
DMARDS
MTX
Sulfasalazine
ANTI TUMOR NECROSIS FACTOR
Etanercept
IL-1 INHIBITOR
Canakinumab
IL 6 RECEPTOR
Tocilizumab
Autoantibody production against self-antigens – inflammatory damage to target organs
FEMALE
skin, joints, kidneys, blood-forming cells, blood vessels and CNS
SYSTEMIC LUPUS ERYTHEMATOSUS
Criteria for diagnosis of SLE
SOAP BRAIN MD
Serositis (pleuritis, pericarditis)
Oral ulcers (painless)
Arthritis (2 or more joints)
Photosensitivity
Blood changes (anemia, leukopenia, low platelet)
Renal disorder (persistent proteinuria, cellular casts)
ANA abnormal titer
Immunological changes (anti-DNA Ab, anti-Sm)
Neurological signs (seizures, frank psychosis)
Malar rash
Discoid rash
Excellent screening tool for SLE but can be (+) in other rheumatic conditions
ANA
More specific for lupus and reflects the degree of disease activity
Anti-DS DNA
Specific for diagnosis of SLE
Anti Smith AB
MC affected organ in MIS-C
Heart
More likely to be correlated with ANA POSITIVITY
anterior uveitis younger age at disease onset female sex asymmetric arthritis lower number of involved joints over time
Risk factors for devt of uveitis in various types of juvenile idiopathic arthritis
oligoarthritis subtype
female
ANA (+)
onset of arthritis earlier than 6 y/o
Clinical manifestations of SPONDYLOARTHRITIS
arthritis of sacroiliac joints arthritis of the hips enthesitis symptomatic uveitis GI inflammation
Reactive arthritis typically follows ENTERIC infection with
Salmonella sp Shigella flexneri Yersinia enterolitica Campylobacter jejuni Organitourinary tract infection w. C. trachomatis
The skin manifestation MOST suggestive of SLE in children
Discoid rash
Recommended for all individuals with SLE if tolerated
Prevents SLE flares, improves lipid profiles and may have beneficial impact in mortality and renal outcomes
HYDROXYCHLOROQUINE
The most serious complication d.t. neonatal lupus
Congenital Heart Block
Common manifestations of Juvenile Dermatomyositis
Heliotrope rash Photosensitivity Facial erythema crossing the nasolabial folds Gottron papules Periungual telangiectasias
Adolescence
Symmetric occurrence
(-) tissue necrosis and gangrene
Raynaud Disease
Hallmark of Behcet disease
ORAL ULCERATION
very painful recurrent involve any location in the oral cavity last 3-10 days heal without scarring
Treatment for Behcet Disease
(-) major organ involvement - COLCHICINE
(+) vascular involvement - CYCLOPHOSPHAMIDE
Primary Sjogren Syndrome
CHILDREN
*recurrent parotitis and recurrent parotid gland enlargement
ADULT
*SICCA SYNDROME - dry mouth, painful mucosa, sensitivity to spicy foods, halitosis, widespread dental caries)
Subtype of JIA with HIGHEST PREVALENCE of AA amyloidosis
Systemic JIA